Standing Order
All companies

Biotech

Telix Pharmaceuticals Limited

TLXNASDAQpure-play
Market cap$2.8B
Conviction4/ 5
HQNorth Melbourne, Victoria, Australia
View full dashboard

For informational purposes only. Not financial advice, not a recommendation to buy or sell any security. Standing Order is a directory and research project, not an advisory service.

Price · 1Y

$8.37

-50.2%

Thesis

Telix Pharmaceuticals is a commercial radiopharmaceutical company built on an approved prostate cancer imaging agent. Diagnostic revenue funds a broadening therapeutic radioligand pipeline across oncology.

Catalysts

  • Illuccix commercial growth
  • Kidney and additional diagnostic approvals
  • Therapeutic radioligand program advancement

Recent events

Material filings, federal awards, and regulatory activity. Impact is scored against market cap.

  • Oct 21
    Financial resultsSEC

    Telix Pharmaceuticals files 6-K containing Q3 2026 results announcement.

  • Sep 30
    RegulatorySEC

    6-K reports FDA Fast Track designation for BiPass program.

  • Sep 21
    PartnershipSEC

    Telix Pharmaceuticals files 6-K on collaboration with ITM.

  • Sep 14
    RegulatorySEC

    Telix Pharmaceuticals 6-K reports FDA approval of Pixclara.

  • Sep 11
    RegulatoryFDA

    FDA approval of original NDA218592 for PIXCLARA (status date 2026-09-11)

  • Sep 2
    Trial initiationSEC

    6-K filing on Phase 3 BIPASS trial enrollment update.

  • Sep 1
    LeadershipSEC

    6-K reports appointment of David at Telix Pharmaceuticals Limited.

  • Aug 20
    Financial resultsSEC

    Telix Pharmaceuticals files 6-K report covering period ended June 30, 2026.

Not financial advice — research and opinion only. Disclosures